Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
High-level waste (HLW) is produced by nuclear reactors and the reprocessing of nuclear fuel. The exact definition of HLW differs internationally. After a nuclear fuel rod serves one fuel cycle and is removed from the core, it is considered HLW. Spent fuel rods contain mostly uranium with fission products and transuranic elements generated in the reactor core. Spent fuel is highly radioactive and often hot. HLW accounts for over 95% of the total radioactivity produced in the process of nuclear electricity generation but it contributes to less than 1% of volume of all radioactive waste produced in the UK. Overall, the 60-year-long nuclear program in the UK up until 2019 produced 2150 m3 of HLW. The radioactive waste from spent fuel rods consists primarily of cesium-137 and strontium-90, but it may also include plutonium, which can be considered transuranic waste. The half-lives of these radioactive elements can differ quite extremely. Some elements, such as cesium-137 and strontium-90 have half-lives of approximately 30 years. Meanwhile, plutonium has a half-life that can stretch to as long as 24,000 years. The amount of HLW worldwide is increasing by about 12,000 tonnes per year. A 1000-megawatt nuclear power plant produces about 27 tonnes of spent nuclear fuel (unreprocessed) every year. For comparison, the amount of ash produced by coal power plants in the United States is estimated at 130,000,000 t per year and fly ash is estimated to release 100 times more radiation than an equivalent nuclear power plant.
He would subsequently be recognised as engaged in essential war work through his role in broadcasting for the BBC and documentary filmmaking, work he took up in 1941 after he and Caitlin moved to London, leaving their son with Caitlin's mother at Blashford. Thomas produced film scripts for the Strand Film Company, work which provided him with a much needed financial mainstay throughout the war years and his first regular source of income since working for the South Wales Daily Post. In February 1941, Swansea was bombed by the Luftwaffe in the Three Nights' Blitz. Castle Street was one of many streets that suffered badly; rows of shops, including the Kardomah Café, were destroyed. Thomas walked through the bombed-out shell of the town centre with his friend Bert Trick. Upset at the sight, he concluded: "Our Swansea has died". Thomas later wrote a feature programme for the radio, Return Journey, describing how: "The Kardomah Café was razed to the snow, the voices of the coffee drinkers—poets, painters, and musicians in their beginnings—all lost". The programme, produced by Philip Burton, was first broadcast on 15 June 1947. The Kardomah Café reopened on Portland Street after the war. In early 1943, Thomas began a relationship with Pamela Glendower, one of several affairs he had during his marriage. The affairs either ran out of steam or were halted after Caitlin discovered his infidelity. In March 1943, Caitlin gave birth to a daughter, Aeronwy, in London. They lived in a run-down studio in Chelsea, made up of a single large room with a curtain to separate the kitchen.
Focke-Wulf A 3 Focke-Wulf A 4 Focke-Wulf A 5 Focke-Wulf A 6 Focke-Wulf A 7 Focke-Wulf A 16 – light transport aircraft, 1924. First design built by Focke-Wulf. Focke-Wulf A 17 Möwe (Gull) – 8-passenger airliner, 1927. Focke-Wulf A 20 Habicht (Hawk) – 4-passenger feederliner, 1927. Focke-Wulf A 21 Photomöwe – aerial photography version of A 17, 1929. Focke-Wulf A 26 – engine testbed Focke-Wulf A 28 – A 20 with Bristol Titan engine Focke-Wulf A 29 – production version of A 17, 1929. Focke-Wulf A 32 Bussard (Buzzard) – airliner, 1930. Focke-Wulf A 33 Sperber (Sparrowhawk) – 3-passenger airliner, 1930. Focke-Wulf A 36 Mastgans (Mast Goose) – mail plane, 1931. Focke-Wulf A 38 Möwe (Gull) – 10-passenger airliner, 1931. Focke-Wulf F 19 Ente (Duck) – experimental civil utility aircraft, 1927. Focke-Wulf GL 18 – light transport aircraft developed from the A 16, 1926. Focke-Wulf GL 22 – revised GL 18, 1927. Focke-Wulf K 23 Buchfink (Chaffinch) – two-seat reconnaissance aircraft, 1928. Focke-Wulf AL 101 D Albatros Focke-Wulf S 1 – trainer, 1925. Focke-Wulf S 2 – two-seat trainer, 1928. Focke-Wulf S 24 Kiebitz (Lapwing) – two-seat sports biplane, 1928. Focke-Wulf S 39 – two-seat reconnaissance parasol monoplane, 1931-1932. Focke-Wulf W 4 – reconnaissance floatplane, 1927. Focke-Wulf W 7 – maritime patrol biplane, 1932.
== Preparation and reactions == DNCB is produced commercially by the nitration of p-nitrochlorobenzene with a mixture of nitric and sulfuric acids. Other methods afford the compound less efficiently include the chlorination of 1,3-dinitrobenzene, nitration of o-nitrochlorobenzene and the dinitration of chlorobenzene. By virtue of the two nitro substituents, the chloride in DNCB is particularly susceptible to nucleophilic substitution, at least relative to simple chlorobenzene. In this way, the compound is a precursor to many other compounds. For example, the chloride can be replaced by iodide easily. Reaction of DNCB with ammonia gives 2,4-dinitrochloroaniline, again a versatile precursor. DNCB is as a substrate in glutathione S-transferase, relevant to activity assays.
On August 31, 2022, FIFA president Gianni Infantino confirmed that six CONCACAF teams would qualify for the World Cup, with Canada, Mexico, and the United States automatically qualifying as hosts. This was confirmed by the FIFA Council on February 14, 2023. Immediately prior to the 67th FIFA Congress, the FIFA Council approved the slot allocation during a meeting in Manama, Bahrain. This included an inter-confederation playoff tournament involving six teams to decide the last two FIFA World Cup spots. The six teams in the playoffs comprised one team from each confederation excluding UEFA, and one additional team from the confederation of the host countries (CONCACAF). Two of those teams were seeded based on the World Rankings, and they played the winners of two knockout matches between the four unseeded teams for the two FIFA World Cup berths. The four-match tournament was played in Mexico, one of the host countries, and was also used as a test event for the FIFA World Cup. The ratification of slot allocation also gave the OFC a guaranteed berth in the final tournament for the first time: the 2026 FIFA World Cup was the first tournament in which all six confederations had at least one guaranteed berth and also the first time since the 2010 edition in which all confederations had a team qualify for the World Cup finals. Of the 48 qualified teams, 26 also appeared in the 2022 edition. Highlights include:
Sources: en.wikipedia.org
where ABCD+ is selected by MS1, dissociates into molecule AB and ion CD+. The ion is selected in the second mass spectrometry stage MS2 then undergoes further fragmentation to form ion D+ which is selected in the third mass spectrometry stage MS3 and detected. Multiple reaction monitoring (MRM) is the application of selected reaction monitoring to multiple product ions from one or more precursor ions, for example
=== Other uses === Risperidone has demonstrated clinical benefit as an augmentation agent in the management of (unipolar) non-psychotic treatment-resistant depression alongside antidepressant treatment. Atypical antipsychotics, such as risperidone, are among the most common augments for antidepressant therapy. Such usage occurs off-label in most jurisdictions and the risk of adverse effects (e.g., weight gain, movement disorders) must be carefully weighed against the clinical benefit. Risperidone has shown promise in treating therapy-resistant obsessive–compulsive disorder, when serotonin reuptake inhibitors alone are not sufficient. Risperidone has proven to be effective in treatment of aggression associated with attention deficit hyperactivity disorder (ADHD), or with another mental condition. Risperidone has not demonstrated a benefit in the treatment of eating disorders or personality disorders, except for limited evidence in schizotypal personality disorder.
== Sources and composition == Silk is not a single substance but a family of fibrous proteins spun by several different animals, and the silks used as biomaterials differ both in their origin and in the proteins they contain.
== Etymology == The term comes from French coup d'État, literally meaning a 'stroke of state' or 'blow of state'. In French, the word État (French: [eta]) is capitalized when it denotes a sovereign political entity. One early use within text translated from French was in 1785 in a printed translation of a letter from a French merchant, commenting on an arbitrary decree, or arrêt, issued by the French king restricting the import of British wool. In the British press, the phrase came to be used to describe the various murders by Napoleon's alleged secret police, the Gens d'Armes d'Elite, who executed the Duke of Enghien: "the actors in torture, the distributors of the poisoning draughts, and the secret executioners of those unfortunate individuals or families, whom Bonaparte's measures of safety require to remove. In what revolutionary tyrants call grand[s] coups d'état, as butchering, or poisoning, or drowning, en masse, they are exclusively employed."
=== Phase 2 === 18F PI-2620 ([18F]PI-2620; PI-2620) – positron-emission tomography (PET) enhancer – diagnosis [16] AB-1005 (AAV2-GDNF; AMT-140; adeno-associated-virus-GDNF therapy) – gene transference and glial cell line-derived neurotrophic factor (GDNF) expression stimulant [17] Affitope PD01 (ACI-7104; ACI-7104.056; Affitope-PD01A; PD-01; PD-01A) – peptide vaccine against α-synuclein [18] Altropane 123I (dopamine transporter (DAT) imaging radiopharmaceutical) – dopamine reuptake inhibitor (DRI) and single-photon emission-computed tomography (SPECT) enhancer – diagnosis [19] Apomorphine inhalation (AZ-009; Staccato® Apomorphine) – non-selective dopamine receptor agonist and other actions [20] Apomorphine intranasal (AL-101) – non-selective dopamine receptor agonist and other actions [21] Aprepitant/pramipexole (ALTO-208; CTC-413) – combination of aprepitant (neurokinin NK1 receptor antagonist) and pramipexole (dopamine D2-like receptor agonist) [22] Bezisterim (17α-ethynyl-5-androstene-3β,7β,17β-triol; HE-3286; NE-3107; Triolex) – undefined mechanism of action (synthetic androstenetriol analogue and anti-inflammatory) [23] Blarcamesine (AE-37; ANA001; ANAVEX 2-73) – sigma σ1 receptor agonist, muscarinic acetylcholine M1 receptor agonist, and ionotropic glutamate NMDA receptor agonist [24] Buspirone/zolmitriptan (AV-2860; JM-010) – combination of buspirone (serotonin 5-HT1A receptor agonist and other actions) and zolmitriptan (serotonin 5-HT1B and 5-HT1D receptor agonist) – drug-induced dyskinesia in Parkinson's disease [25] Carbidopa/levodopa (DopaFuse; levodopa/carbidopa continuous release) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [26] Carbidopa/levodopa intranasal (INP-107; POD™ carbidopa/levodopa) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [27] DA-9805 – antioxidant and mitochondrial protein modulator [28] Deferiprone (CGP-37391; CMX-001; CP-020; CP-20; CRMD-001; Ferriprox; Kelfer; L1; Upkanz) – chelating agent [29] EPI-589 ((R)-troloxamide quinone; kinoquinone) – NAD(P)H dehydrogenase (quinone) modulator and antioxidant [30] FNP-150 – undefined mechanism of action [31] Gemfibrozil (FHL-301) – peroxisome proliferator-activated receptor alpha (PPARα) agonist [32] Glovadalen (UCB-0022) – dopamine D1 receptor positive allosteric modulator [33] GRF-6021 (AKST-6021) – plasma protein fraction and neurogenesis stimulant [34] ION-859 (BIIB-094; ION859; IONIS-BIIB7Rx) – leucine-rich repeat kinase 2 (LRRK2) inhibitor [35] Lazucirnon (AKST-4290; ALK-429; ALK-4290) – chemokine CCL11 inhibitor [36] Levetiracetam low-dose (AGB-101) – synaptic vesicle glycoprotein 2A (SV2A) modulator [37] Levodopa (TR-012001) – dopamine precursor and indirect non-selective dopamine receptor agonist [38] Levodopa intranasal (INP103; POD™ levodopa) – dopamine precursor and indirect non-selective dopamine receptor agonist [39] Matsupexole (AM006; KDT-3594) – dopamine receptor agonist [40] Minzasolmin (DLX-313; UCB-0599) – α-synuclein misfolding inhibitor [41] Nilotinib (KFRX-01) – Bcr-Abl tyrosine kinase inhibitor and discoidin domain receptor antagonist [42] Pariceract (BIA 28-6156; LTI-291) – β-glucocerebrosidase (GCase) activator [43] Pegsebrenatide (NLY-01; Olaedin; pegylated exenatide; TLY-001) – glucagon-like peptide-1 receptor (GLP1R) agonist [44] Pirepemat (IRL-752) – various actions [45] Pramipexole – dopamine D2, D3, and D4 receptor agonist [46] Prasinezumab (NEOD-002; PRX-002; RG-7935; RO-7046015) – monoclonal antibody against α-synuclein [47] Pridopidine (ACR-16; ASP-2314; FR-310826; Huntexil; Nurzigma; TV-7820) – sigma σ1 receptor agonist and other actions [48] Radotinib (IY-5511; Supect) – Bcr-Abl tyrosine kinase inhibitor and other actions [49] Risvodetinib (Ikt-148009; IkT148009; risvo) – Bcr-Abl tyrosine kinase inhibitor [50] Squalamine (ENT-01; Enterin-01; kenterin) – various actions [51] Tributyrin (glyceryl tributyrate) – butyric acid (butyrate) prodrug and various actions [52] [53] Usnoflast (ZYIL-1) – NLR family pyrin domain containing 3 (NLRP3) inhibitor [54] Vatiquinone (α-tocotrienol quinone; vincerenone; EPI-743 and PTC-743) – coenzyme Q10 analogue, antioxidant, oxidoreductase inhibitor, 15-lipoxygenase (15-LOX/ALOX15) inhibitor [55] Vodobatinib (K-0706; SCO-088; SUN-K706; SUN-K0706) – Bcr-Abl tyrosine kinase inhibitor [56] VTX-3232 – NLR family pyrin domain containing 3 (NLRP3) inhibitor [57] Vutiglabridin (HSG-4112) – paraoxonase 2 (PON2) agonist and glabridin analogue [58] WID-2101 – undefined mechanism of action [59] XJN-010 – undefined mechanism of action [60]
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.